Recently, exciting news has come from Bohong Stem Cell, a subsidiary of the park-based Bohong Group! The kick-off meeting for the Phase I clinical study of "Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Rheumatoid Arthritis," led by Peking University People's Hospital with the participation of Shandong Bohong Stem Cell, was successfully held. By leveraging cutting-edge regenerative medicine technology to tackle the challenges of treating rheumatoid arthritis, this milestone demonstrates the formidable strength and innovative commitment of park enterprises in the fields of cell therapy and biomedicine.

On March 24, this significant clinical study was officially launched. Led by Professor Li Zhanguo of Peking University People's Hospital, which serves as the main venue and the leading clinical study site responsible for overall coordination, the trial benefits from the deep expertise Professor Li and his team have accumulated over years of diagnosis, treatment, and basic research on rheumatoid arthritis, laying a solid academic foundation for its advancement. In the same month, Qilu Hospital of Shandong University joined as a sub-center, with related work spearheaded by Professor Shu Qiang. The powerful collaboration between these two authoritative institutions ensures the study proceeds in a scientific, standardized, and efficient manner.

This clinical trial focuses on the core strengths of umbilical cord mesenchymal stem cells, leveraging a dual mechanism of "immune modulation + tissue repair." By precisely inhibiting the activation of abnormal immune cells and reducing synovial inflammation, while simultaneously secreting various cytokines to promote the regeneration and repair of damaged joints and bone tissues, this approach is expected to break the treatment dilemma of "only controlling symptoms without achieving repair." It offers a new pathway for relapse control and long-term prognosis.

Numerous positive studies have already supported the use of umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis (RA), demonstrating effective improvement in disease activity, restoration of immune homeostasis, and an excellent long-term safety profile. This multi-center clinical trial, conducted simultaneously across the country, further standardizes the research process and strengthens data support, driving a transformation in RA treatment from "symptomatic control" to "causal repair" and bringing new hope to millions of patients.

The launch of this clinical study marks a significant strategic breakthrough for Bohong Stem Cell in the field of regenerative medicine. It represents a key step toward building a high-level medical center integrating "medical services, education, research, and production," and vividly reflects the innovative vitality of Blue Pharma Valley · Life Island Park.

Looking ahead, Blue Pharma Valley · Life Island Park will continue to deepen its engagement in biomedicine and regenerative medicine. Relying on the public service platform for pilot-scale conversion of cell products, the park will provide enterprises with one-stop support covering standardized stem cell preparation, quality testing, ethical review, and clinical application guidance. It will also persistently deliver ground services such as clinical resource matching, full-cycle project tracking, and precise policy implementation. Through these pragmatic measures, the park aims to create a thriving cell therapy industry ecosystem, injecting strong momentum into the high-quality development of China's biomedical industry!